A Real-World Systematic Analysis of Driver Mutations’ Prevalence in Early- and Advanced-Stage NSCLC: Implications for Targeted Therapies in the Adjuvant Setting

SIMPLE SUMMARY: The development of oncogene-targeted drugs has radically changed the course of non small cell lung carcinoma (NSCLC) in the advanced stage. Recently, the ADAURA trial demonstrated the efficacy of Osimertinib also in the adjuvant setting of EGFR-mutated NSCLC. This raises the question...

Descripción completa

Detalles Bibliográficos
Autores principales: Terrenato, Irene, Ercolani, Cristiana, Di Benedetto, Anna, Gallo, Enzo, Melucci, Elisa, Casini, Beatrice, Rollo, Francesca, Palange, Aldo, Visca, Paolo, Pescarmona, Edoardo, Melis, Enrico, Gallina, Filippo, Sacconi, Andrea, Cecere, Fabiana Letizia, Landi, Lorenza, Cappuzzo, Federico, Ciliberto, Gennaro, Buglioni, Simonetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221477/
https://www.ncbi.nlm.nih.gov/pubmed/35740637
http://dx.doi.org/10.3390/cancers14122971

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221477/
https://www.ncbi.nlm.nih.gov/pubmed/35740637
http://dx.doi.org/10.3390/cancers14122971

Ejemplares similares